Status:
COMPLETED
Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy
Lead Sponsor:
Assiut University
Conditions:
Metastatic Colorectal Adenocarcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advan...
Detailed Description
Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti\_EGFR targeted therapy between left colon and rectal cancer
Eligibility Criteria
Inclusion
- age above 18
- Both sex
- Performance status zero to one according to ECOG scale system
- Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.
- Patients diagnosed with left colon and rectal cancer.
- Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.
- Patients diagnosed with metastatic stage.
- K-RAS wild type.
Exclusion
- Second malignancy
- Histo-pathological types other than adenocarcinoma.
- Right colon cancer patients.
- Patients refused receiving anti\_EGFR targeted therapy.
- Patients with any abnormalities preventing to receive chemotherapy.
- Early stages of colorectal cancer.
- K-RAS mutant type.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06083974
Start Date
January 1 2015
End Date
December 30 2022
Last Update
October 16 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.